← Oncology Approval Tracker

FDA DECISION ·

Koselugo

selumetinib · AstraZeneca

FDA approvalNew dosing regimenNF1-associated plexiform neurofibromas
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

The FDA removed the fasting requirement for selumetinib capsules in the then-labeled population: children aged 2 years and older with NF1 and symptomatic, inoperable plexiform neurofibromas.

LAMPGEN ANALYSIS

Why it matters

More flexible administration can help families fit twice-daily treatment into meals and school schedules.

What research teams should watch

Update medication counseling and study drug administration instructions; maintain the required eye and cardiac follow-up.

PRIMARY RECORDS

Sources